Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole

References

• NeofytosDLuKHatfield-SeungAEpidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapyDiagn Microbiol Infect Dis20137514414923142166
   PubMed Web of Science ®Google Scholar
• GrollAHCastagnolaECesaroSFourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantationLancet Oncol201415e327e34024988936
   PubMed Web of Science ®Google Scholar
• LanternierFCypowyjSPicardCPrimary immunodeficiencies underlying fungal infectionsCurr Opin Pediatr20132573674724240293
   PubMed Web of Science ®Google Scholar
• HachemRHannaHKontoyiannisDJiangYRaadIThe changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancyCancer2008112112493249918412153
   PubMed Web of Science ®Google Scholar
• PaganoLCairaMCandoniAThe epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 studyHaematologica2006911068107516885047
   PubMed Web of Science ®Google Scholar
• ChoSYChoiHYOpportunistic fungal infection among cancer patients. A ten-year autopsy studyAm J Clin Pathol1979724617621495566
   PubMed Web of Science ®Google Scholar
• GoodmanJLWinstonDJGreenfieldRAA controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantationN Engl J Med199226;32613845851
   Web of Science ®Google Scholar
• HofHA new, broad-spectrum azole antifungal: posaconazole – mechanisms of action and resistance, spectrum of activityMycoses200649Suppl 12616961575
   PubMed Web of Science ®Google Scholar
• MunayyerHKMannPAChauASPosaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and moldsAntimicrob Agents Chemother2004483690369615388421
   PubMed Web of Science ®Google Scholar
• KwonDSMylonakisEPosaconazole: a new broad-spectrum antifungal agentExpert Opin Pharmacother200781167117817516880
   PubMed Web of Science ®Google Scholar
• GuarascioAJSlainDReview of the new delayed-release oral tablet and intravenous dosage forms of posaconazolePharmacotherapy20153520821925644669
   PubMed Web of Science ®Google Scholar
• McKeageKPosaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infectionsDrugs201575439740625595699
   PubMed Web of Science ®Google Scholar
• Lass-FlörlCSusceptibility testing in Aspergillus species complexClin Microbiol Infect201420Suppl 6495324372722
   PubMed Web of Science ®Google Scholar
• CastanheiraMMesserSAJonesRNFarrellDJPfallerMAActivity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infectionsInt J Antimicrob Agents20144432032625129315
   PubMed Web of Science ®Google Scholar
• SabatelliFPatelRMannPAIn vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeastsAntimicrob Agents Chemother2006502009201516723559
   PubMed Web of Science ®Google Scholar
• SunQNFothergillAWMcCarthyDIRinaldiMGGraybillJRIn vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetesAntimicrob Agents Chemother2002461581158211959605
   PubMed Web of Science ®Google Scholar
• Noxafil® (posaconazole) [package insert]Whitehouse Station, NJMerck and Co, Inc2014
   Google Scholar
• US Food Drug AdministrationNoxafil^® (posaconazole) oral suspension Product informationSilver SpringUS Food and Drug Administration Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022003s007lbl.pdfAccessed March 21, 2015
   Google Scholar
• KrieterPFlanneryBMusickTGohdesMMartinhoMCourtneyRDisposition of posaconazole following single-dose oral administration in healthy subjectsAntimicrob Agents Chemother2004483543355115328123
   PubMed Web of Science ®Google Scholar
• GhosalAHapangamaNYuanYIdentification of human UDP-glucuronosyltransferase enzyme(s) responsible fort the glucuronidation of posaconazole (Noxofil)Drug Metab Dispos20043226727114744950
   PubMed Web of Science ®Google Scholar
• CourtneyRSansoneASmithWPosaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal diseaseJ Clin Pharmacol20054518519215647411
   PubMed Web of Science ®Google Scholar
• KrishnaGSansone-ParsonsAMartinhoMKantesariaBPediconeLPosaconazole plasma concentrations in juvenile patients with invasive fungal infectionAntimicrob Agents Chemother20075181281817210771
   PubMed Web of Science ®Google Scholar
• CourtneyRPaiSLaughlinMLimJBatraVPharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsAntimicrob Agents Chemother2003472788279512936975
   PubMed Web of Science ®Google Scholar
• GubbinsPOKrishnaGSansone-ParsonsAPharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipientsAntimicrob Agents Chemother2006501993199916723557
   PubMed Web of Science ®Google Scholar
• GrossBNIhorstGJungMWäschREngelhardtMPosaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literaturePharmacotherapy2013331117112523864486
   PubMed Web of Science ®Google Scholar
• BryantAMSlainDCumpstonACraigMA post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with hematologic malignancy receiving posaconazole prophylaxisInt J Antimicrob Agents20113726626921236645
   PubMed Web of Science ®Google Scholar
• CourtneyRRadwanskiELimJLaughlinMPharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy menAntimicrob Agents Chemother20044880480814982768
   PubMed Web of Science ®Google Scholar
• KrishnaGMaLMartinhoMO’MaraESingle-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspensionAntimicrob Agents Chemother2012564196420122615291
   PubMed Web of Science ®Google Scholar
• KrishnaGMaLMartinhoMPrestonRAO’MaraEA new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteersJ Antimicrob Chemother2012672725273022833639
   PubMed Web of Science ®Google Scholar
• DuarteRFLópez-JiménezJCornelyOAPhase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropeniaAntimicrob Agents Chemother2014585758576525049247
   PubMed Web of Science ®Google Scholar
• CornelyOADuarteRFHaiderSPhase 3 Pharmacokinetics (PK) and Safety Study of Posaconazole (POS) Tablet in Patients at Risk for Invasive Fungal InfectionAbstract presented at: 23rd European congress of clinical microbiology and infectious diseasesApril 28, 2013Berlin
   Google Scholar
• KraftWKChangPSvan IerselMLWaskinHKrishnaGKersemaekersWMPosaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjectsAntimicrob Agents Chemother2014584020402524798274
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationHighlights of Prescribing InformationSilver SpringUS Food and Drug Administration Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022003s008,022027s001lbl.pdfAccessed March 21, 2015
   Google Scholar
• CornelyOAMaertensJWinstonDJPosaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropeniaN Engl J Med200735634835917251531
   PubMed Web of Science ®Google Scholar
• UllmannAJLiptonJHVesoleDHPosaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseN Engl J Med200735633534717251530
   PubMed Web of Science ®Google Scholar
• TackeDBuchheidtDKarthausMPrimary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and OncologyAnn Hematol2014931449145624951122
   PubMed Web of Science ®Google Scholar
• DöringMEikemeierMCabanillas StanchiKMAntifungal prophylaxis with posaconazole vs fluconazole or itraconazole in pediatric patients with neutropeniaEur J Clin Microbiol Infect Dis Epub2142015
   Web of Science ®Google Scholar
• DöringMMüllerCJohannPDAnalysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantationBMC Infect Dis20121226323082876
   PubMed Web of Science ®Google Scholar
• DöringMBlumeOHaufeSComparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantationEur J Clin Microbiol Infect Dis20143362963824173819
   PubMed Web of Science ®Google Scholar
• YunusSPieperSKolveHGoletzGJürgensHGrollAHAzole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal auditJ Antimicrob Chemother20146981582024198097
   PubMed Web of Science ®Google Scholar
• O’SullivanAKPandyaAPapadopoulosGCost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United StatesValue Health20091266667319508661
   PubMed Web of Science ®Google Scholar
• Tahami MonfaredAAO’SullivanAKRotsteinCPapadopoulosGEconomic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in CanadaCan J Infect Dis Med Microbiol201223596423730310
   PubMed Web of Science ®Google Scholar
• AthanasakisKPetrakisIKyriopoulosJPosaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in GreeceJ Med Econ20131667868423448409
   PubMedGoogle Scholar
• GrauSde la CámaraRSabaterFJCost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in SpainBMC Infect Dis2012128322471553
   PubMed Web of Science ®Google Scholar
• MichalletMGangneuxJPLafumaACost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare systemJ Med Econ201114283521175376
   PubMedGoogle Scholar
• GreinerRAMeierYPapadopoulosGO’SullivanAKImhofACost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in SwitzerlandOncology20107817218020414005
   PubMed Web of Science ®Google Scholar
• JansenJPO’SullivanAKLugtenburgESpanLFJanssenJJStamWBEconomic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the NetherlandsAnn Hematol20108991992620383504
   PubMed Web of Science ®Google Scholar
• LundbergJHöglundMBjörkholmMÅkerborgÖEconomic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in SwedenClin Drug Investig201434483489
   PubMed Web of Science ®Google Scholar
• LazzaroCEconomic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndromeInfez Med20101891103 Italian20610931
   PubMedGoogle Scholar
• ConantMMShaBEProiaLAUse of posaconazole delayed-release tablets for treatment of invasive aspergillosisMycoses Epub2272015
   Web of Science ®Google Scholar
• SungAHMarcellaSWXieYAn update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United StatesJ Med Econ Epub32201518
   Web of Science ®Google Scholar
• ShenYHuangXJWangJXPosaconazole vs fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label studyInt J Clin Pharmacol Ther20135173874523924680
   PubMed Web of Science ®Google Scholar
• KungHCJohnsonMDDrewRHSaha-ChaudhuriPPerfectJRClinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort studyCancer Med2014366767324644249
   PubMed Web of Science ®Google Scholar
• GirmeniaCFrustaciAMGentileGPosaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experienceHaematologica20129756056722102706
   PubMed Web of Science ®Google Scholar
• PetersonLOstermannJRiegerHOstermannHRiegerCTPosaconazole prophylaxis – impact on incidence of invasive fungal disease and antifungal treatment in haematological patientsMycoses20135665165823710592
   PubMed Web of Science ®Google Scholar
• VehreschildJJRüpingMJWisplinghoffHClinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohortJ Antimicrob Chemother2010651466147120410061
   PubMed Web of Science ®Google Scholar
• Sánchez-OrtegaIPatiñoBArnanMClinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantationBone Marrow Transplant20114673373920697369
   PubMed Web of Science ®Google Scholar
• PaganoLCairaMCandoniAEvaluation of the practice of anti-fungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registryClin Infect Dis2012551515152122955439
   PubMed Web of Science ®Google Scholar
• WangCHKanLPLinHAClinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in TaiwanJ Microbiol Immunol Infect Epub10132014
   Google Scholar
• DevanlayCTavernier-TardyEBourmaudAImpact of Fluconazole versus Posaconazole Prophylaxis on the Incidence of Fungal Infections in Patients Receiving Induction Chemotherapy for Acute Myeloid LeukemiaBiomed J Epub10302014
   Web of Science ®Google Scholar
• ChaftariAMHachemRYRamosEComparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantationTransplantation20129430230822814329
   PubMed Web of Science ®Google Scholar